Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comprehensive Omics Analysis Uncovers Alterations in Sphingolipid Metabolism of Tumor-Influenced MDSCs in Cervical Cancer

  • By

  • Qiuwen Mai

  • Chudan Chi

  • Xiaojun Wang

  • Yili Chen

  • Qiaojian Zou

  • Qianrun Chen

  • Feitianzhi Zeng

  • Mengxun Wei

  • Yanfei Chen

  • Aiting Wang

  • Yan Liao

  • Yuzhou Xiao

  • Xinjie Li

  • Qing Yan

  • Liping Zhan

  • Hongsuo Wei

  • Xu Jing

  • Qiqiao Du

  • Junxiu Liu

  • September 18, 2026

Share

  • 1

    Cervical cancer is a leading cause of death among females globally, with its tumor microenvironment playing a critical role in disease progression.

  • 2

    Myeloid-derived suppressor cells (MDSCs) are key components of the cervical cancer tumor microenvironment, influencing immune evasion and disease progression.

  • 3

    MDSC expansion correlates positively with tumor burden and negatively with therapy response and overall survival in cervical cancer patients.

  • 4

    Proteomic and metabolomic profiling revealed significant alterations in lipid metabolism, particularly sphingolipid metabolism, in tumor-conditioned MDSCs.

  • 5

    Integrated analysis identified Kng1–sphingosine 1-phosphate as a principal protein–metabolite network in cervical cancer cell-conditioned MDSCs.

Original Source(s)

Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer

  • by Qiuwen Mai, Chudan Chi, Xiaojun Wang, Yili Chen, Qiaojian Zou, Qianrun Chen, Feitianzhi Zeng, Mengxun Wei, Yanfei Chen, Aiting Wang, Yan Liao, Yuzhou Xiao, Xinjie Li, Qing Yan, Liping Zhan, Hongsuo Wei, Xu Jing, Qiqiao Du, Junxiu Liu

  • September 18, 2026

Related Content

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min
Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

  • by

  • September 15, 2026

  • 3 min
Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women